Zai Lab Ltd. (ZLAB) catalysts

Upcoming FDA decisions and readouts we track for Zai Lab Ltd., each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 11 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Zai Lab Ltd. (ZLAB, listed on Nasdaq). It concerns Povetacicept (IgA nephropathy).

First on the list: the PDUFA date for Povetacicept (IgA nephropathy), dated 30 Nov 2026.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.

Ticker: ZLAB
Next catalyst: 30 Nov 2026
Type: PDUFA date
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Zai Lab Ltd. ZLAB · Nasdaq	Povetacicept	IgA nephropathy	30 Nov 2026 in 54d	PDUFA date	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states the FDA accepted the BLA "for accelerated approval in adults with immunoglobulin A nephropathy (IgAN), with a PDUFA target action date of November 30, 2026." Source: 8-K exhibit 99.1, filed 06 Aug 2026 · verified 11 Sep 2026

Companies working on related conditions

Climb Bio (CLYM)IgA nephropathy / autoimmune (CD19 antibody)
Jade Biosciences (JBIO)IgA nephropathy (APRIL antibody); Rheumatoid arthritis; Dermatomyositis
Vera Therapeutics (VERA)IgA nephropathy

Also due in Q4 2026

Merck & Co. (MRK)PDUFA date for Ifinatamab deruxtecan (I-DXd), 10 Oct 2026
BridgeBio Pharma (BBIO)PDUFA date for BBP-418, 27 Nov 2026
Cytokinetics (CYTK)PDUFA date for Aficamten, 14 Nov 2026
Capricor Therapeutics (CAPR)PDUFA date (extended) for Deramiocel, 22 Nov 2026
Savara Inc. (SVRA)PDUFA date for Molgramostim, 22 Nov 2026
Cogent Biosciences (COGT)PDUFA date for Bezuclastinib, 30 Nov 2026